US20170182135A1 - Dry powder fibrin sealant - Google Patents
Dry powder fibrin sealant Download PDFInfo
- Publication number
- US20170182135A1 US20170182135A1 US15/456,004 US201715456004A US2017182135A1 US 20170182135 A1 US20170182135 A1 US 20170182135A1 US 201715456004 A US201715456004 A US 201715456004A US 2017182135 A1 US2017182135 A1 US 2017182135A1
- Authority
- US
- United States
- Prior art keywords
- microparticles
- composition
- trehalose
- fibrinogen
- thrombin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims description 17
- 239000000843 powder Substances 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 239000011859 microparticle Substances 0.000 claims abstract description 52
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 42
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 42
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 42
- 229960004072 thrombin Drugs 0.000 claims abstract description 35
- 108090000190 Thrombin Proteins 0.000 claims abstract description 33
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 32
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 32
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000003556 assay Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- 238000002965 ELISA Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims 5
- 230000000087 stabilizing effect Effects 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 206010052428 Wound Diseases 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 description 20
- 229940074410 trehalose Drugs 0.000 description 20
- 239000003094 microcapsule Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 238000000889 atomisation Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000010894 electron beam technology Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940106780 human fibrinogen Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012419 revalidation Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940074409 trehalose dihydrate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- -1 as calcium chloride Chemical compound 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A61K41/0019—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Definitions
- This invention relates to a dry powder fibrin sealant.
- WO97/44015 describes a dry powder fibrin sealant based on micro-particles of fibrinogen and thrombin. This has been demonstrated to be an easy-to-use, stable and efficacious topical haemostat. The product can be used immediately, without reconstitution. On contact with aqueous fluid such as blood, the exposed active thrombin immediately converts the exposed fibrinogen into insoluble fibrin polymers.
- the novel fibrin sealant is a blend of spray-dried fibrinogen and thrombin, each of which has been individually co-spray dried with an excipient.
- a number of excipients have been used in the fibrin sealant formulation to stabilise the active ingredients fibrinogen and thrombin and the physical stability evaluated.
- the fibrin sealant formulation has been exposed to electron beam/gamma irradiation or heat sterilisation in order to terminally sterilize the product.
- the results of the evaluation indicate that trehalose is the most effective excipient in terms of protein protection during stability storage and electron beam exposure.
- the superior stabilization afforded by the trehalose-based formulations may be attributed to the higher glass transition temperature of trehalose compared to other excipients such as sucrose.
- the influence of different parameters on the efficacy of the product was determined in pig liver biopsy models and pig liver resection models.
- Fibrin sealant powders with a fibrinogen content of at least 4% w/w and a thrombin content of at least 139 IU/g were shown to be effective in stopping severe bleeding.
- the optimum fibrinogen and thrombin content was 7.5% w/w and ⁇ 400 IU/g, respectively.
- Fibrinogen and thrombin from 3 different suppliers all performed equally well, demonstrating the robustness of the product.
- the invention provides a fibrin sealant product that demonstrates high efficacy at low fibrinogen levels in severely bleeding wounds and can be terminally sterilized using standard irradiation methods.
- FIG. 1 is a plot of the particle size distribution of spray-dried thrombin:trehalose according to the invention.
- FIG. 2 is a plot of the particle size distribution of spray-dried fibrinogen:trehalose according to the invention.
- Respective fibrinogen-containing and thrombin-containing soluble microparticles can be formulated together, in stable, dry form. This formulation can be subsequently activated, as desired, to give a fibrin sealant that is useful in wound therapy and surgical repair. It can meet the primary objectives of achieving good flow properties, enhanced, effective delivery to the active site, and dissolution only at the site, not in the delivery system.
- the content of fibrinogen in the microparticles containing it may be about 0.1 to 50% w/w, preferably about 0.5 to 20 w/w.
- the content of thrombin in the microparticles containing it may be about 10 to 20,000 IU/g, preferably about 25 to 1,000 IU/g.
- Microparticles comprising fibrinogen or thrombin may be prepared by the procedures described in WO92/18164, WO96/09814 and WO96/18388. These spray-drying and associated particle manipulation processes enable the production of soluble protein microcapsules with defined size distribution, e.g. of up to 50 ⁇ m in diameter. For example, as described in those documents, the microparticles may be produced reproducibly, e.g. with 90% or more (by volume) up to 30 ⁇ m, e.g. 10 to 20 ⁇ m, in size.
- Microparticles of the invention are preferably prepared by spray-drying. Typically, a 2-fluid nozzle is used which utilises compressed air during the atomisation process; this results in the production of hollow microparticles.
- the maximum particle size (X50) of microparticles that can be manufactured using this atomisation system on the Niro Mobile Minor spray dryer is ⁇ 30 ⁇ m.
- Preferred X50 values for the microparticles of the invention are between 5 and 50 microns, most preferably between 10 and 20 microns.
- Microparticles of the invention may be prepared by spray-drying a solution of the active component with trehalose alone.
- An alternative procedure comprises co-spray-drying, in which fibrinogen or thrombin and another wall-forming material are formulated and spray-dried, to give microparticles in which the active component is incorporated in the wall of the particle.
- the product is preferably amorphous or in the form of a glass, as measured by a suitable technique such as FTIR or DSC., with a glass transition temperature of at least 50 Celsius, most preferably at least 80 Celsius.
- the fibrinogen or thrombin may be full-length or any active fragment thereof. Fragments are known; see Coller et al, J. Clin. Invest. 89:546-555 (1992). Fibrinogen raw material may be a frozen solution, although, lyophilised powder which requires reconstitution prior to spray-drying may be used.
- Suitable other proteins may be naturally occurring or recombinant. They may act as “wall-forming materials”, as described in W09 2 / 1 8164, where various examples are given.
- a preferred material is HSA (human serum albumin).
- HSA human serum albumin
- fibrinogen is spray-dried alone or in the presence of varying amounts of excipients such as HSA (e.g. fibrinogen: HSA ratios of 1:1, 1:3, 3:1) and trehalose.
- HSA human serum albumin
- Other suitable substitutes for HSA include surfactants, such as Tween 20, Tween 80, Poloxamer 407 or Poloxamer 188.
- Calcium ion e.g. as calcium chloride
- calcium chloride may be added to the microcapsules after processing.
- Microparticles of the invention may be sterilised, if necessary or desired. Sterile processing, electron beam irradiation, Y-irradiation and ethylene oxide are examples of suitable techniques.
- the components of the microcapsules in a fibrin sealant of the invention are preferably water-soluble, and the microparticles are preferably obtained by spray-drying a suitable solution, the microparticles that are obtainable may be free-flowing, discrete and substantially anhydrous, with a residual moisture content preferably no greater than 5% w/w, most preferably no greater than 3% w/w.
- the compounds of fibrin sealant in accordance with this invention are not activated until they are wetted, e.g. by coming into contact with liquid at a wound site.
- the active components may therefore be delivered as a dry mixture, although separate application of the different microparticles is also envisaged.
- a dry powder fibrin sealant product may be of particular value where application to a large surface area is required. This includes surgery and repair of traumatic injuries to various organs such as the liver and spleen.
- a further advantageous application is in skin grafting for burns patients, and specifically where skin epidermal sheets are cultured in vitro and then transferred to the wound site.
- the use of fibrin sealant in the latter indication may be particularly effective in patients with extensive burns, providing a biocompatible anchorage for skin grafts. It may also be suitable in the treatment of topical ulcers.
- Spray-dried fibrinogen microparticles were prepared by dissolving 73.8 g human fibrinogen in 1650 mL water containing 275.1 g trehalose dihydrate. The resultant solution was spray-dried on a Niro Mobile Minor spray dryer using the following operating parameters:
- Inlet temperature 160° C.
- Atomisation type 2—Fluid Nozzle
- Liquid insert 0.5 mm
- the spray-dried powder had a particle size (X50, geometric diameter) of 18.4 ⁇ m and a fibrinogen content of 152 mg/g.
- the moisture content (Karl-Fischer) was 2%.
- Spray-dried thrombin microparticles were prepared by dissolving 751,230 IU human thrombin in 1653 mL water containing 11.5 g calcium chloride dihydrate and 507.3 g trehalose dihydrate. The resultant solution was spray-dried on a Niro Mobile Minor spray dryer using the following operating parameters:
- Inlet temperature 160° C.
- Atomisation type 2—Fluid Nozzle
- Liquid insert 0.5 mm
- the spray-dried powder had a particle size (X50, geometric diameter) of 12.5 ⁇ m and a thrombin content of 977 IU/g.
- the moisture content (Karl-Fischer) was 3%.
- the two spray-dried powders were blended in a 1:1% w/w ratio using a drum mixer at 18 rpm for 15 minutes.
- the resultant blend had a particle size of 15.5 ⁇ m, and a fibrinogen content of 69.1 mg/g.
- FIG. 1 shows the cumulative distribution as follows:
- FIG. 2 shows the cumulative distribution as follows:
- the spray-drying parameters were selected so as to produce particles in the region of 10 ⁇ m.
- microcapsules batches were aliquoted into clear 10 ml glass vials both as separate components and as excipient-matched blends.
- a stability study at 4° C. was conducted over four weeks. Four timepoints were selected; initial, 1 week, 2 weeks and 4 weeks, and the following assays were employed to compare the effect of the different excipients on the stability and bioactivity retention.
- Fibrinogen Analysis used a polyconal antibody to human fibrinogen as a capture antibody and a second peroxidise-labelled antibody to human fibrinogen is used for detection in a chromogenic assay.
- Thrombin Analysis was based on a commercial substrate which is sensitive to thrombin and gives a colour change which can be measured.
- the initial rate of change in absorbance is proportional to thrombin concentration.
- Particle Size was measured using a L5230 Laser Sizer in conjunction with Medium Chain Trigylceride oil to determine the particle size of the spray dried material.
- Thermogravimetric Analysis was carried out to assess moisture content.
- Flow time was the time taken for a microcapsule blend to pass through a funnel of a pre-determined size was used as a comparative measure of flowability between batches.
- Angle of Repose indicates the flowability of a powder and was measured by the calculation of the angle created upon the flow of a powder through a funnel and subsequent accumulation on a flat surface.
- Clot Strength utilises the formulation of a clot from a blend in a plastic syringe. A bead is suspended in the syringe prior to clot formation and the weight required to pull the bead through the clot is recorded.
- Adhesive Strength blends are applied to a piece of rat skin via a 10 ml glass pipette fitted with a compressed air supply. The weight required to separate two pieces of the tissue bonded together by a blend is used as a measurement of adhesive strength.
- This assay is based on a Gottlob skin test method—Gesting and Lerner: Autologous fibrinogen for tissue adhesion haemostatis (1983)). Additional assays were performed at the four week timepoint; SDS PAGE to assess the effects of spray-drying on the structural integrity of the bioactives and a BCA assay for total protein determination. Scanning electron micrographs (SEM) were also obtained for each of the individual formulations.
- Results demonstrated no significant changes over the stability period for either formulation, but the data do suggest a greater retention of activity generated for the trehalose formulation when compared with the sucrose formulation.
- the clot strength values also indicate an increased activity retention with the trehalose formulation.
- the addition of NSA to the trehalose-thrombin formulation showed no significant differences in bioactivity retention compared to the trehalose-thrombin formulation.
- the flow properties were retained over the stability period which is reflected in the consistent adhesive strength values.
- Dry heat viral inactivation step was conducted for 72 hours at 80° C.
- bioanalytical results indicate the excipient trehalose allows a greater retention of the active during the dry heat step.
- Gamma-irradiation employed 25 KG at a rate of 8 KG-hour. Samples were exposed to these irradiation conditions both as separate components and as a 15 blend.
- the conditions investigated in the terminal sterilisation study suggest that trehalose offers a higher level of protection to the protein, as reflected by the activity retention. This observation may also suggest a trehalose formulation may be capable of room temperature storage. Gamma irradiation of the sucrose formulation resulted in a 50% drop in fibrinogen activity. The trehalose formulation was found to have a significantly higher fibrinogen activity retention (70%) as measured by the ELISA and clot strength assays.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application claims the benefit of U.S. application Ser. No. 12/636,718 filed Dec. 12, 2009 which claims priority to U.S. provisional application Ser. No. 61/122,063, filed Dec. 12, 2008, which is incorporated herein by reference in its entirety.
- This invention relates to a dry powder fibrin sealant.
- WO97/44015 describes a dry powder fibrin sealant based on micro-particles of fibrinogen and thrombin. This has been demonstrated to be an easy-to-use, stable and efficacious topical haemostat. The product can be used immediately, without reconstitution. On contact with aqueous fluid such as blood, the exposed active thrombin immediately converts the exposed fibrinogen into insoluble fibrin polymers.
- The novel fibrin sealant is a blend of spray-dried fibrinogen and thrombin, each of which has been individually co-spray dried with an excipient. A number of excipients have been used in the fibrin sealant formulation to stabilise the active ingredients fibrinogen and thrombin and the physical stability evaluated. In addition, the fibrin sealant formulation has been exposed to electron beam/gamma irradiation or heat sterilisation in order to terminally sterilize the product. The results of the evaluation indicate that trehalose is the most effective excipient in terms of protein protection during stability storage and electron beam exposure. The superior stabilization afforded by the trehalose-based formulations may be attributed to the higher glass transition temperature of trehalose compared to other excipients such as sucrose.
- The influence of different parameters on the efficacy of the product was determined in pig liver biopsy models and pig liver resection models. The efficacy of the fibrin sealant powder to stop severely bleeding injuries, with blood loss of >10 ml/min, was enhanced by the opportunity to apply pressure directly after administration of the product. Fibrin sealant powders with a fibrinogen content of at least 4% w/w and a thrombin content of at least 139 IU/g were shown to be effective in stopping severe bleeding. The optimum fibrinogen and thrombin content was 7.5% w/w and ˜400 IU/g, respectively. Fibrinogen and thrombin from 3 different suppliers all performed equally well, demonstrating the robustness of the product. Terminal sterilization of the product using electron beam or gamma irradiation of up to 15 or 25 kGy had no effect on the efficacy of the product and is considered to reduce the risk of bacterial contamination before use. In summary, the invention provides a fibrin sealant product that demonstrates high efficacy at low fibrinogen levels in severely bleeding wounds and can be terminally sterilized using standard irradiation methods.
-
FIG. 1 is a plot of the particle size distribution of spray-dried thrombin:trehalose according to the invention. -
FIG. 2 is a plot of the particle size distribution of spray-dried fibrinogen:trehalose according to the invention. - Respective fibrinogen-containing and thrombin-containing soluble microparticles can be formulated together, in stable, dry form. This formulation can be subsequently activated, as desired, to give a fibrin sealant that is useful in wound therapy and surgical repair. It can meet the primary objectives of achieving good flow properties, enhanced, effective delivery to the active site, and dissolution only at the site, not in the delivery system.
- The content of fibrinogen in the microparticles containing it may be about 0.1 to 50% w/w, preferably about 0.5 to 20 w/w. The content of thrombin in the microparticles containing it may be about 10 to 20,000 IU/g, preferably about 25 to 1,000 IU/g.
- Microparticles comprising fibrinogen or thrombin may be prepared by the procedures described in WO92/18164, WO96/09814 and WO96/18388. These spray-drying and associated particle manipulation processes enable the production of soluble protein microcapsules with defined size distribution, e.g. of up to 50 μm in diameter. For example, as described in those documents, the microparticles may be produced reproducibly, e.g. with 90% or more (by volume) up to 30 μm, e.g. 10 to 20 μm, in size.
- Microparticles of the invention are preferably prepared by spray-drying. Typically, a 2-fluid nozzle is used which utilises compressed air during the atomisation process; this results in the production of hollow microparticles. The maximum particle size (X50) of microparticles that can be manufactured using this atomisation system on the Niro Mobile Minor spray dryer is ˜30 μm. Preferred X50 values for the microparticles of the invention are between 5 and 50 microns, most preferably between 10 and 20 microns.
- Microparticles of the invention may be prepared by spray-drying a solution of the active component with trehalose alone. An alternative procedure comprises co-spray-drying, in which fibrinogen or thrombin and another wall-forming material are formulated and spray-dried, to give microparticles in which the active component is incorporated in the wall of the particle. The product is preferably amorphous or in the form of a glass, as measured by a suitable technique such as FTIR or DSC., with a glass transition temperature of at least 50 Celsius, most preferably at least 80 Celsius.
- The fibrinogen or thrombin may be full-length or any active fragment thereof. Fragments are known; see Coller et al, J. Clin. Invest. 89:546-555 (1992). Fibrinogen raw material may be a frozen solution, although, lyophilised powder which requires reconstitution prior to spray-drying may be used.
- Suitable other proteins may be naturally occurring or recombinant. They may act as “wall-forming materials”, as described in W092/18164, where various examples are given. A preferred material is HSA (human serum albumin). For example, fibrinogen is spray-dried alone or in the presence of varying amounts of excipients such as HSA (e.g. fibrinogen: HSA ratios of 1:1, 1:3, 3:1) and trehalose. Other suitable substitutes for HSA include surfactants, such as Tween 20, Tween 80, Poloxamer 407 or Poloxamer 188.
- Calcium ion, e.g. as calcium chloride, may be incorporated in the thrombin feedstock. Alternatively, calcium chloride may be added to the microcapsules after processing.
- Microparticles of the invention may be sterilised, if necessary or desired. Sterile processing, electron beam irradiation, Y-irradiation and ethylene oxide are examples of suitable techniques.
- Although the components of the microcapsules in a fibrin sealant of the invention are preferably water-soluble, and the microparticles are preferably obtained by spray-drying a suitable solution, the microparticles that are obtainable may be free-flowing, discrete and substantially anhydrous, with a residual moisture content preferably no greater than 5% w/w, most preferably no greater than 3% w/w. This means that the compounds of fibrin sealant in accordance with this invention are not activated until they are wetted, e.g. by coming into contact with liquid at a wound site. The active components may therefore be delivered as a dry mixture, although separate application of the different microparticles is also envisaged.
- A dry powder fibrin sealant product may be of particular value where application to a large surface area is required. This includes surgery and repair of traumatic injuries to various organs such as the liver and spleen. A further advantageous application is in skin grafting for burns patients, and specifically where skin epidermal sheets are cultured in vitro and then transferred to the wound site. The use of fibrin sealant in the latter indication may be particularly effective in patients with extensive burns, providing a biocompatible anchorage for skin grafts. It may also be suitable in the treatment of topical ulcers.
- The following Examples illustrate the invention.
- Spray-dried fibrinogen microparticles were prepared by dissolving 73.8 g human fibrinogen in 1650 mL water containing 275.1 g trehalose dihydrate. The resultant solution was spray-dried on a Niro Mobile Minor spray dryer using the following operating parameters:
- Inlet temperature: 160° C.
- Atomisation type: 2—Fluid Nozzle
- Liquid insert: 0.5 mm
- Atomisation pressure: 0.5 bar
- Feed rate: 18 g/minute
- The spray-dried powder had a particle size (X50, geometric diameter) of 18.4 μm and a fibrinogen content of 152 mg/g. The moisture content (Karl-Fischer) was 2%.
- Spray-dried thrombin microparticles were prepared by dissolving 751,230 IU human thrombin in 1653 mL water containing 11.5 g calcium chloride dihydrate and 507.3 g trehalose dihydrate. The resultant solution was spray-dried on a Niro Mobile Minor spray dryer using the following operating parameters:
- Inlet temperature: 160° C.
- Atomisation type: 2—Fluid Nozzle
- Liquid insert: 0.5 mm
- Atomisation pressure: 0.5 bar
- Feed rate: 18 g/minute
- The spray-dried powder had a particle size (X50, geometric diameter) of 12.5 μm and a thrombin content of 977 IU/g. The moisture content (Karl-Fischer) was 3%.
- The two spray-dried powders were blended in a 1:1% w/w ratio using a drum mixer at 18 rpm for 15 minutes. The resultant blend had a particle size of 15.5 μm, and a fibrinogen content of 69.1 mg/g.
- The respective particle size distributions are shown in
FIGS. 1 and 2 .FIG. 1 shows the cumulative distribution as follows: -
x0/μm Q3/% 1.80 6.71 2.20 8.45 2.60 10.02 3.00 11.48 3.60 13.58 4.40 16.36 5.20 19.25 6.20 23.15 7.40 28.33 8.60 33.97 10.00 40.87 12.00 50.65 15.00 64.07 18.00 75.17 21.00 83.61 25.00 91.27 30.00 96.53 36.00 99.11 42.00 99.85 50.00 100.00 60.00 100.00 72.00 100.00 86.00 100.00 102.00 100.00 122.00 100.00 146.00 100.00 174.00 100.00 206.00 100.00 246.00 100.00 294.00 100.00 350.00 100.00 -
Evaluation: WINDOX 5.1.2.0, HRLD Product: Fibrocaps Revalidation: Density: 1.00 g/cm3, shape factor: 1.00 Reference measurement: Disp. Meth: Set up for Fibrocaps R/M 08-20 11:42:05 Copt = 1.56% Contamination: 0.00% -
Trigger condition: Fibrocaps User parameters: Time base: 200.00 ms Batch Number: PV Thrombin Start: c.opt >=0.2% Formulation: EM/08/126 Valid: always Name: aks Stop: 2.000 sc.opt <=0.2% or Run Number: Run 110000 s real time -
FIG. 2 shows the cumulative distribution as follows: -
x0/μm Q3/% 1.80 2.68 2.20 3.58 2.60 4.53 3.00 5.52 3.60 7.06 4.40 9.19 5.20 11.39 6.20 14.20 7.40 17.63 8.60 21.10 10.00 25.15 12.00 30.88 15.00 39.17 18.00 46.85 21.00 53.70 25.00 61.53 30.00 69.48 36.00 76.91 42.00 82.47 50.00 87.80 60.00 92.11 72.00 95.07 86.00 96.87 102.00 97.94 122.00 98.72 146.00 99.34 174.00 99.81 206.00 100.00 246.00 100.00 294.00 100.00 350.00 100.00 -
Evaluation: WINDOX 5.1.2.0, HRLD Product: Fibrocaps Revalidation: Density: 1.00 g/cm3, shape factor: 1.00 Reference measurement: Disp. Meth: Set up for Fibrocaps R/M 08-29 13:35:41 Copt = 7.30% Contamination: 0.00% -
Trigger condition: Fibrocaps User parameters: Time base: 200.00 ms P1: SD Fibrinogen: trehalose clinical Start: c.opt >=0.2% P2: EM/08/129 Valid: always P3: TR Stop: 2.000 sc.opt <=0.2% or P4: run 1 10000 s real time - Four batches of microparticles were produced, using the following formulations and a Mini spray dryer.
-
- 200 mg/ml trehalose—200 units/ml thrombin
- 200 mg/ml sucrose—200 units/ml thrombin—1% HSA w-v
- 200 mg/ml trehalose—40 mg/fibrinogen
- 200 mg/ml sucrose—40 mg/ml fibrinogen.
- The spray-drying parameters were selected so as to produce particles in the region of 10 μm.
- Thrombin Formulation:
-
- Inlet temperature: 130° C.
- Outlet temperature: −80° C.
- Atomisation Airflow: 5/-min
- Drying Airflow: 5/-sec
- Feed Rate: 5.0 g-min
- Fibrinogen Formulation:
-
- Inlet temperature: 130° C.
- Outlet temperature: −83° C.
- Atomisation Airflow: 15/-min
- Drying Airflow: 51-sec
- Feed Rate: 3.0 g-min
- Each of the microcapsules batches was aliquoted into clear 10 ml glass vials both as separate components and as excipient-matched blends. A stability study at 4° C. was conducted over four weeks. Four timepoints were selected; initial, 1 week, 2 weeks and 4 weeks, and the following assays were employed to compare the effect of the different excipients on the stability and bioactivity retention.
- Fibrinogen Analysis used a polyconal antibody to human fibrinogen as a capture antibody and a second peroxidise-labelled antibody to human fibrinogen is used for detection in a chromogenic assay.
- Thrombin Analysis was based on a commercial substrate which is sensitive to thrombin and gives a colour change which can be measured. The initial rate of change in absorbance is proportional to thrombin concentration.
- Particle Size was measured using a L5230 Laser Sizer in conjunction with Medium Chain Trigylceride oil to determine the particle size of the spray dried material.
- Thermogravimetric Analysis was carried out to assess moisture content.
- Flow time was the time taken for a microcapsule blend to pass through a funnel of a pre-determined size was used as a comparative measure of flowability between batches.
- Angle of Repose indicates the flowability of a powder and was measured by the calculation of the angle created upon the flow of a powder through a funnel and subsequent accumulation on a flat surface.
- Packed and tap density were measured using the Jolting Volume Meter and the values used in Carrs Compressibility Index (% CCI).
- Clot Strength utilises the formulation of a clot from a blend in a plastic syringe. A bead is suspended in the syringe prior to clot formation and the weight required to pull the bead through the clot is recorded.
- Adhesive Strength: blends are applied to a piece of rat skin via a 10 ml glass pipette fitted with a compressed air supply. The weight required to separate two pieces of the tissue bonded together by a blend is used as a measurement of adhesive strength. (This assay is based on a Gottlob skin test method—Gesting and Lerner: Autologous fibrinogen for tissue adhesion haemostatis (1983)). Additional assays were performed at the four week timepoint; SDS PAGE to assess the effects of spray-drying on the structural integrity of the bioactives and a BCA assay for total protein determination. Scanning electron micrographs (SEM) were also obtained for each of the individual formulations.
- Results demonstrated no significant changes over the stability period for either formulation, but the data do suggest a greater retention of activity generated for the trehalose formulation when compared with the sucrose formulation. The clot strength values also indicate an increased activity retention with the trehalose formulation. The addition of NSA to the trehalose-thrombin formulation showed no significant differences in bioactivity retention compared to the trehalose-thrombin formulation. The flow properties were retained over the stability period which is reflected in the consistent adhesive strength values.
- SDS PAGE data demonstrated the retention of structural integrity post-30 spray-drying.
- Scanning electron micrographs revealed similar morphology for all formulations.
- Dry heat viral inactivation step was conducted for 72 hours at 80° C.
- The individual fibrinogen and thrombin components were assessed using ELISA and chromogenic assays respectively and the blends were analysed using the clot strength assay. The results are documented in Table 1.
-
TABLE 1 Dry Heat Sterilisation Bioactivity - Concentration per 100 mg Clot Strength Sample spray-dried Product (g) Trehalose - Thrombin 101.6 units (97%) * microcapsules Trehalose - Fibrinogen 14.17 mg (103%) * microcapsules Trehalose - Active blend * 64.8 g Sucrose - Thrombin 93.8 units (89%) * microcapsules Sucrose - Fibrinogen 11.04 mg (80.5) * microcapsules Sucrose - Active blend * 62.7 g Theoretical thrombin concentration = 105 units - 100 mg spray-dried product Theoretical fibrinogen concentration = 13.7 mg - 100 mg spray-dried product % Retention is shown in brackets Expected clot strength = ~70 g - The bioanalytical results indicate the excipient trehalose allows a greater retention of the active during the dry heat step.
- Gamma-irradiation employed 25 KG at a rate of 8 KG-hour. Samples were exposed to these irradiation conditions both as separate components and as a 15 blend.
- The components were assessed using ELISA and chromogenic assays respectively and the blends examined via the clot strength assay. The results are documented in Table 2.
-
TABLE 2 Gamma Irradiation Sterilisation Bioactivity - Concentration per 100 mg Clot Strength Sample spray-dried Product (g) Trehalose - Thrombin 71 units (71%) * microcapsules Trehalose Fibrinogen 10.3 mg (73%) * microcapsules Trehalose - Active blend * 59.5 g Sucrose - Thrombin 71 units (71%) microcapsules Sucrose - Fibrinogen 7.7 mg (55.5 * microcapsules Sucrose - Active blend * 36.9 g % Retention is shown in brackets. - The conditions investigated in the terminal sterilisation study (72 hours at 80° C.) suggest that trehalose offers a higher level of protection to the protein, as reflected by the activity retention. This observation may also suggest a trehalose formulation may be capable of room temperature storage. Gamma irradiation of the sucrose formulation resulted in a 50% drop in fibrinogen activity. The trehalose formulation was found to have a significantly higher fibrinogen activity retention (70%) as measured by the ELISA and clot strength assays.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/456,004 US20170182135A1 (en) | 2008-12-12 | 2017-03-10 | Dry powder fibrin sealant |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12206308P | 2008-12-12 | 2008-12-12 | |
US12/636,718 US9827205B2 (en) | 2008-12-12 | 2009-12-12 | Dry powder fibrin sealant |
US15/456,004 US20170182135A1 (en) | 2008-12-12 | 2017-03-10 | Dry powder fibrin sealant |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/636,718 Continuation US9827205B2 (en) | 2008-12-12 | 2009-12-12 | Dry powder fibrin sealant |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170182135A1 true US20170182135A1 (en) | 2017-06-29 |
Family
ID=42240815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/636,718 Expired - Fee Related US9827205B2 (en) | 2008-12-12 | 2009-12-12 | Dry powder fibrin sealant |
US15/456,004 Abandoned US20170182135A1 (en) | 2008-12-12 | 2017-03-10 | Dry powder fibrin sealant |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/636,718 Expired - Fee Related US9827205B2 (en) | 2008-12-12 | 2009-12-12 | Dry powder fibrin sealant |
Country Status (1)
Country | Link |
---|---|
US (2) | US9827205B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0909136D0 (en) | 2009-05-28 | 2009-07-01 | Profibrix Bv | Dry powder composition |
MD4117C1 (en) * | 2010-07-30 | 2012-02-29 | Институт Химии Академии Наук Молдовы | Powder with haemostatic and regenerative properties (variants) and process for the production thereof |
WO2014135689A2 (en) * | 2013-03-07 | 2014-09-12 | Profibrix Bv | Powder formulation |
IL242984A0 (en) * | 2015-12-08 | 2016-02-29 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, preparation and uses thereof |
US10159720B2 (en) * | 2015-12-08 | 2018-12-25 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, preparation and uses thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE20824T1 (en) * | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING. |
DE3175003D1 (en) * | 1981-06-25 | 1986-08-28 | Serapharm Gmbh & Co Kg | Enriched plasma derivative for promoting wound sealing and wound healing |
US4442655A (en) * | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
DE229810T1 (en) * | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | PROTECTION OF PROTEINS AND SIMILAR. |
US4752466A (en) * | 1987-08-31 | 1988-06-21 | Johnson & Johnson Products, Inc. | Thrombin aerosol |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US7189410B1 (en) | 1990-11-27 | 2007-03-13 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
WO1994023788A1 (en) * | 1993-04-20 | 1994-10-27 | Medchem Products, Inc. | Apparatus and method for applying a particulate hemostatic agent to living tissue |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
ATE235919T1 (en) * | 1994-06-02 | 2003-04-15 | Elan Drug Delivery Ltd | METHOD FOR PREVENTING AGGREGATION OF PROTEINS/PEPTIDES DURING REHYDRATION OR DEFROSTING |
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
BR9509171A (en) | 1994-09-29 | 1997-09-16 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
JP4223548B2 (en) | 1994-12-07 | 2009-02-12 | ジ・アメリカン・ナショナル・レッド・クロス | Supplemental or non-complementary tissue sealants, their preparation and use |
US5955108A (en) * | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
EP0914096B1 (en) * | 1996-05-17 | 2003-08-13 | Elan Drug Delivery Limited | Microparticles and their use in wound therapy |
GB9621825D0 (en) | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
US6162241A (en) * | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
US7572769B2 (en) | 1998-12-23 | 2009-08-11 | Csl Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
US6916911B1 (en) * | 1999-08-13 | 2005-07-12 | Omrix Biopharmaceuticals Sa | Use of fibrinogen multimers |
US6183498B1 (en) * | 1999-09-20 | 2001-02-06 | Devore Dale P. | Methods and products for sealing a fluid leak in a tissue |
US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
US7544177B2 (en) * | 2002-01-24 | 2009-06-09 | The Regents Of The University Of California | Aerosol device to deliver bioactive agent |
NL1019873C2 (en) | 2002-01-31 | 2003-08-04 | Harimex Bv | Method for preparing a blood plasma powder, and applications thereof. |
US7811558B2 (en) * | 2004-08-12 | 2010-10-12 | Cellphire, Inc. | Use of stabilized platelets as hemostatic agent |
WO2007022485A2 (en) | 2005-08-19 | 2007-02-22 | Becton, Dickinson And Company | Sterilization of biosensors |
WO2008019128A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
US8846105B2 (en) * | 2010-01-08 | 2014-09-30 | Profibrix, B.V. | Dry powder fibrin sealant |
-
2009
- 2009-12-12 US US12/636,718 patent/US9827205B2/en not_active Expired - Fee Related
-
2017
- 2017-03-10 US US15/456,004 patent/US20170182135A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100150900A1 (en) | 2010-06-17 |
US9827205B2 (en) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170182135A1 (en) | Dry powder fibrin sealant | |
US20190269764A1 (en) | Powder formulation | |
JP4024302B2 (en) | Microparticles and their use in wound treatment | |
KR101967085B1 (en) | Process for making dry and stable hemostatic compositions | |
EP2771027B1 (en) | Hemostatic compositions | |
KR101957625B1 (en) | Process for making dry and stable hemostatic compositions | |
CA2874290C (en) | Dry haemostatic composition | |
JP6726852B2 (en) | Dry composition for use in hemostasis and wound healing | |
JP6918799B2 (en) | Thrombin microcapsules | |
CA2761903C (en) | Dry powder fibrin sealant | |
RU2242996C2 (en) | Composition of fibrin tissue adhesive and method for its obtaining | |
KR20130121702A (en) | Process for making dry and stable hemostatic compositions | |
CA2928963A1 (en) | Dry composition comprising an extrusion enhancer | |
WO2010136818A2 (en) | Dry powder fibrin sealant | |
WO2010136819A2 (en) | Dry powder fibrin sealant | |
CN107690333B (en) | Method for preparing powder containing human coagulation factor protein and lactic acid polymer | |
KR20000011085A (en) | Microparticles and their use in wound therapy | |
WO2003037395A1 (en) | Wafer for wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY;REEL/FRAME:049823/0213 Effective date: 20190719 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INO THERAPEUTICS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: IKARIA THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: THERAKOS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: ST SHARED SERVICES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: INFACARE PHARMACEUTICAL CORPORATION, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MEH, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: IMC EXPLORATION COMPANY, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT VETERINARY, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: LIEBEL-FLARSHEIM COMPANY LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: LAFAYETTE PHARMACEUTICALS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: CNS THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: LUDLOW LLC (F/K/A LUDLOW CORPORATION), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT US POOL LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT CARRIBEAN, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT FINANCE GMBH, SWITZERLAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT CB LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 Owner name: MALLINCKRODT INTERNATIONAL FINANCE S.A., LUXEMBOURG Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0542 Effective date: 20231114 |